1525 - Low dose rate (LDR) brachytherapy for intermediate and high-risk prostate cancer

Page last updated: 06 November 2019

Application Detail



Description of Medical Service

LDR Brachytherapy is the insertion of tiny radioactive capsules or ‘seeds’ into the prostate gland. Generally, 80-120 seeds will be implanted. The radiation from the seeds targets the tumour and destroys the cancerous cells. The seeds are inserted via a hollow needle through the perineum. The procedure is guided by transrectal ultrasound.

Description of Medical Condition

Cancer of the prostate gland that is classified as intermediate or high-risk. Intermediate risk prostate cancer is defined as having a Prostate Specific Antigen (PSA) measurement of 10-20 nanograms per millilitre of blood (ng/ml) and/or a Gleason score of 7 and/or a tumour classified as T2b-c. High-risk prostate cancer is classified as having a PSA of greater than 20 and/or a Gleason score of 8-10 and/or a tumour classified as T3 OR 2 or more intermediate risk features.

Reason for Application

Amendment to MBS item(s)

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form

Application Form (Word 145 KB)
Application Form (PDF 285 KB)

Consultation Survey

Consultation Survey (Word 508 KB)
Consultation Survey (PDF 95 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (Word 675 KB)
Public Summary Document (PDF 1675 KB)

Meetings for this Application


12-13 April 2018


13 June 2019


1-2 August 2019